Search Results
Your search for it matches 15595 pages
Showing 4351 - 4400Italian Study of Electronic Medical Record–Assisted Telephone Follow-up of Breast Cancer Survivors During the COVID-19 Pandemic
In an Italian single-institution study reported in JCO Oncology Practice, Merz et al evaluated the use of electronic medical record–assisted telephone follow-up (E-TFU) of breast cancer survivors to minimize hospital exposure over a 3-month period during the COVID-19 pandemic. The strategy was...
Expert Point of View: Ajay K. Nooka, MD, MPH
Ajay K. Nooka, MD, MPH, Associate Professor of Hematology and Medical Oncology at Emory University and Medical Director, Winship Research Informatics Shared Resource at Winship Cancer Institute, Atlanta, considered the presentations on bispecific T-cell–engaging antibodies in myeloma to be among...
New Targets Explored for Bispecific T-Cell–Engaging Antibodies in Myeloma
B-cell maturation antigen (BCMA) is the most frequent target of immunotherapies in relapsed or refractory multiple myeloma, but bispecific T-cell–engaging (BiTE) antibodies with novel targets are also achieving promising results. Studies presented at the 2020 American Society of Hematology (ASH)...
COA Submits Letter to Governors, Public Health Officials to Request Independent Oncology Practices Be Given Priority Approval to Administer COVID-19 Vaccines
Today, leadership from the Community Oncology Alliance (COA) sent a letter urging the nation's governors and public health officials to prioritize supplying cancer treatment practices with COVID-19 vaccines and allowing the practices to administer the vaccines. The letter, signed by Kashyap Patel,...
Palbociclib Plus Endocrine Therapy vs Capecitabine for Patients With HR-Positive, HER2-Negative Breast Cancer: The PEARL Trial
Although patients with hormone receptor (HR)-positive, HER2-negative, aromatase inhibitor–resistant metastatic breast cancer maintained quality of life for a longer time following treatment with palbociclib plus either exemestane or fulvestrant than capecitabine, those receiving chemotherapy...
Expert Point of View: Alphonse G. Taghian, MD
Alphonse G. Taghian, MD, Professor at Harvard Medical School and Co-Director of Breast Cancer Research Program at Massachusetts General Hospital, Boston, said that these results from the PRIME II trial are quite similar to those of the older CALGB study first initiated in 1994.1 Both studies had a ...
Can Postoperative Whole-Breast Irradiation Be Safely Omitted in Older Women With Low-Risk Breast Cancer?
Omitting postoperative radiotherapy with whole-breast irradiation may not compromise 10-year overall survival or increase the risk of developing metastasis in most women 65 years and older with low-risk breast cancer, according to results of the large randomized PRIME II trial reported at the 2020...
Rates of Eligible People Missing Timely Cancer Screenings: A Canadian Analysis
New research published by Abdel-Rahman in JNCCN—Journal of the National Comprehensive Cancer Network found more than one-third of eligible people miss timely screening tests for colorectal cancer, and at least one-quarter appear to miss timely screening tests for breast and cervical cancers....
Record Drop in Cancer Mortality for Second Straight Year Due to Improved Lung Cancer Treatment Reported in ‘Cancer Statistics, 2021’
Overall cancer death rates in the United States dropped continuously from 1991 through 2018, for a total decrease of 31%, including a 2.4% decline from 2017 to 2018. These findings were reported in the American Cancer Society’s “Cancer Statistics, 2021” article, published by Rebecca L. Siegel, MPH, ...
Sean Khozin, MD, MPH, Named New Chief Executive Officer of ASCO’s CancerLinQ
Sean Khozin, MD, MPH, has been named Chief Executive Officer of CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO. A board-certified oncologist, physician-scientist, and data science expert, Dr. Khozin is a proven leader and visionary in deploying cutting-edge data science and technology...
Expert Point of View: Sagar Lonial, MD
Sagar Lonial, MD, the Anne and Bernard Gray Family Chair in Cancer, Chair and Professor of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, commented on the APOLLO trial for The ASCO Post. “APOLLO is a highly awaited study, as the use of daratumumab plus...
Subcutaneous Daratumumab Meets Primary Endpoint in APOLLO Trial in Myeloma
The first phase III study to evaluate the subcutaneous form of daratumumab has met its primary endpoint, investigators of the APOLLO trial reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 The triplet of daratumumab, pomalidomide, and low-dose dexamethasone ...
New Study Investigates Role of Ultraviolet Radiation in Conjunctival Melanoma
Ultraviolet (UV) radiation may contribute to the development of a rare type of eye cancer, conjunctival melanoma, according to research published by Mundra et al in Nature Communications. The new study has revealed similar genetic changes in patients with conjunctival melanoma to those with...
Association Between Toxoplasma gondii Infection and Risk of Glioma
A new study published by Hodge et al in the International Journal of Cancer suggests a link between Toxoplasma gondii infection and the risk of glioma in adults. The report found that people who have glioma are more likely to have antibodies to T gondii than a similar group that was cancer-free....
Comprehensive Multiomic Resource for HPV-Negative Head and Neck Cancers
In a comprehensive molecular characterization of the most common type of head and neck cancer, researchers from the United States and Poland have clarified the contribution of key cancer-associated genes, proteins, and signaling pathways in these cancers, while proposing possible new treatment...
FDA Issues Alert Regarding SARS-CoV-2 Viral Mutation to Health-Care Providers and Clinical Laboratory Staff
The U.S. Food and Drug Administration (FDA) is alerting clinical laboratory staff and health-care providers that it is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests....
Transmission of Maternal Cancer in Two Infants From Mothers With Cervical Cancer During Delivery
In a brief report published in The New England Journal of Medicine, Arakawa et al described the identification of lung cancer in two children that likely resulted from transmission of maternal cervical cancer tumor cells during vaginal delivery. As noted by the investigators, the transmission of...
Invasive Diagnostic Procedure Complication Rates After Lung Cancer Screening
In a study reported in a research letter in JAMA Network Open, Zhao et al found that the rate of complications from invasive diagnostic procedures after low-dose computed tomography (CT) lung cancer screening in the community setting was lower than a prior estimate—but still higher than reported in ...
Three vs Four Courses of Chemotherapy in Younger Patients With AML
As reported in the Journal of Clinical Oncology by Burnett et al, findings from the phase III MRC AML17 trial indicated that four courses of chemotherapy, compared to three courses, reduced the cumulative incidence of relapse and improved relapse-free survival, but not overall survival, in younger...
Facebook Posts and the Spread of Incorrect Information About Perceived Risks of HPV Vaccination
The human papillomavirus (HPV) is the most common sexually transmitted infection in the United States, according to the Centers for Disease Control and Prevention (CDC). HPV is associated with health problems—including cancers—but a vaccine for the virus has been available since 2006. The CDC...
Study Focuses on Single-Cell Analysis of Peritoneal Carcinomatosis
Researchers profiled more than 45,000 individual cells from patients with peritoneal carcinomatosis and defined the extensive cellular heterogeneity, as well as identified two distinct cell subtypes correlated with patient survival. The findings were published by Wang et al in Nature Medicine....
Feasibility Study of Radical Cystectomy vs Intravesical BCG for High-Grade, Non–Muscle Invasive Bladder Cancer
As reported in the Journal of Clinical Oncology by Catto et al, the BRAVO-Feasibility study showed that recruitment of patients with high-grade, non–muscle invasive bladder cancer into a randomized trial comparing radical cystectomy vs intravesical bacillus Calmette-Guérin (BCG) proved difficult,...
FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines
On January 4, U.S. Food and Drug Administration (FDA) Commissioner Stephen M. Hahn, MD, and Director of the FDA’s Center for Biologics Evaluation and Research Peter Marks, MD, PhD, issued the following statement on FDA-authorized dosing schedules for each COVID-19 vaccine. Two different mRNA...
Global Burden of Cervical Cancer and Association With HIV
A research team has quantified the effects of infection with the human immunodeficiency virus (HIV) on the development of cervical cancer. Their results show that the risk of developing cervical cancer is six times higher in women who are infected with HIV, and that women who live in Southern and...
Study Clarifies Time-Dependent Effects of Oral Contraceptives on Risk of Ovarian, Endometrial, and Breast Cancers
A comprehensive study involving more than 250,000 women showed that oral contraceptive use may be protective against the development of ovarian and endometrial cancers, but the effect on lifetime risk of breast cancer is more limited. The protective effect on ovarian and endometrial cancers was...
FDA Issues Emergency Use Authorization for Second COVID-19 Vaccine
On December 18, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the second vaccine for the prevention of COVID-19 caused by SARS-CoV-2. The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the United States for use in...
American Cancer Society Report Identifies Critical Gaps and Research Opportunities for Improved Cancer Care
A new report found that despite progress in the decline of cancer mortality, there are still critical gaps, including the need to develop better tools and explore research opportunities that would lead to limiting cancer as a major health concern. This blueprint article completes an eight-part...
Reducing Disparities in Cancer Care for Sexual and Gender Minority Patients
Although efforts have been made by various medical societies, including ASCO, over the past decade to address the needs of sexual and gender minorities in the cancer care setting, research shows that lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ) patients continue to face...
Increase Your Knowledge and Practice of Cultural Competence With ASCO eLearning Course Collection
“Equity: Every Patient. Every Day. Everywhere” was selected by 2020–2021 ASCO President Lori J. Pierce, MD, FASTRO, FASCO, as the theme for her presidential term. As oncology care providers work to put this theme into practice, they can find support in ASCO eLearning’s new Cultural Literacy course...
Pembrolizumab Plus Chemotherapy for Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer
On November 13, 2020, pembrolizumab (Keytruda) was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for use in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple-negative breast cancer with tumors expressing PD-L1 (Combined ...
Anthony Fauci, MD, Encourages Patients With Cancer to Receive COVID-19 Vaccine
The American Society of Hematology (ASH) President Stephanie Lee, MD, MPH, sat down with Anthony Fauci, MD, Director of the National Institutes of Allergy and Infectious Diseases (NIAID) and medical advisor to President-Elect Joseph Biden, for a virtual fireside chat about COVID-19 and cancer at...
Northwell Invests $6M in Comprehensive Cancer Center in Riverhead, New York
Northwell Health recently announced that it will open a $6.2 million, 11,300-square-foot comprehensive cancer center in Riverhead, New York, by the end of this year. The new facility will provide residents of the East End of Long Island access to integrated cancer services in a conveniently located ...
Expert Point of View: Cathy Eng, MD
Cathy Eng, MD, the David H. Johnson Chair in Surgical and Medical Oncology, Co-Leader of the Gastrointestinal (GI) Cancer Research Program, and Co-Director of GI Oncology at Vanderbilt-Ingram Cancer Center in Nashville, as well as Vice Chair of the SWOG GI Committee, said she found the study’s...
Study Reports Highly Skilled Surgeons Significantly Reduce Death From Colon Cancer
To improve long-term survival odds, individuals with early-stage colon cancer should have their surgery performed by highly skilled surgeons. In a study that used video assessment, surgeons with highly ranked skills gave their patients a 69% lower risk of dying at 5 years as compared with their...
John Ryan, JD, Named Senior Vice President and General Counsel at Dana-Farber Cancer Institute
Dana-Farber Cancer Institute has appointed John Ryan, JD, as its Senior Vice President, General Counsel, and Chief Governance Officer. Mr. Ryan has extensive expertise representing health-care and life sciences organizations in public company and nonprofit settings. He has managed a wide range of...
Chronicling a Family’s History of Cancer
Cancer has been an intimate part of Nancy Borowick’s life since her mother, Laurel, was diagnosed with breast cancer in 1997, when Nancy was 12. She began photographing her mother’s journey with the disease after the cancer recurred in 2009 for her final project for the Documentary Photography and ...
Selected ASH Abstracts on Novel Treatments of Polycythemia Vera
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are three abstracts selected from the meeting proceedings focusing on novel therapies for polycythemia vera. For full details of these study...
Sue S. Yom, MD, PhD, FASTRO, Named Editor-in-Chief of ASTRO’s Red Journal
The American Society for Radiation Oncology (ASTRO) announced the appointment of Sue S. Yom, MD, PhD, FASTRO, as Editor-in-Chief of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), ASTRO’s flagship scientific journal. Dr. Yom, who is Vice Chair and Distinguished...
2020 Basser Global Prize Awarded to Bella Kaufman, MD, of Israel’s Sheba Medical Center
The Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania recently announced Bella Kaufman, MD, of the Sheba Medical Center in Tel-Hashomer, Israel, as the recipient of the eighth annual Basser Global Prize. Dr. Kaufman is Director of the Breast Oncology Institute,...
ASH Recognizes Choosing Wisely Champions at Annual Meeting & Exposition
The American Society of Hematology (ASH) recognized three Choosing Wisely Champions, practitioners working to tackle overuse of hematology tests and treatments, at the all-virtual 2020 ASH Annual Meeting & Exposition. Choosing Wisely, a program of the ABIM Foundation and Consumer Reports, aims...
European Experts Tackle HPV-Related Cancers
The prevention of infection with the human papillomavirus (HPV), and its related cancers, has become a focus of the European Cancer Organisation. At the group’s 2020 European Cancer Summit, held virtually, members of the organization’s HPV Action Network convened with other experts to share...
Panel on Global Cancer Control Looks for Ways Forward in a War That’s Proving Hard to Win
Are we winning the war on cancer? It’s not so clear, especially with COVID-19 poised to erase recent gains, panelists said at a session on global cancer control at the 2020 European Cancer Summit, which was sponsored by the European Cancer Organisation. “We know what we have to do. My question is...
Addressing Inequality in Cancer Care on a Global Scale
It has become a familiar theme of late: Inequities exist in all aspects of cancer care. Although study after study documents problems with access to care and poorer cancer outcomes among underrepresented groups, less is heard about organized efforts to address these issues. This critical topic was...
IU Simon Researcher Receives $1.3 Million Grant to Improve Breast Cancer Treatment for Black Women
Harikrishna Nakshatri, PhD, who is identifying the unique biology that may make Black women more susceptible to aggressive breast cancer, received a $1.3 million grant from the Department of Defense–Congressionally Directed Medical Research Program’s breast cancer research program. Dr. -Nakshatri...
Intratumoral Injections May Boost Neoadjuvant Response in Resectable Melanoma
Studies reported at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting, which was held virtually, showed promise for the use of intratumoral injections of novel immunotherapies in treating advanced, resectable melanoma. In the 3-year interim analysis of a global phase II randomized...
Expert Point of View: Omid Hamid, MD
Omid Hamid, MD, Chief of Research/Immuno-Oncology at The Angeles Clinic & Research Institute and Co-Director of the Cutaneous Malignancy Program at Cedars-Sinai Cancer Center, Los Angeles, commented on the investigational use of bempegaldesleukin in melanoma. “The role of interleukin-2 [Il-2]...
Novel Combination Under Study in First-Line Treatment of Metastatic Melanoma
A first-line regimen combining the novel interleukin-2 (Il-2) agonist bempegaldesleukin (NKTR-214) with nivolumab showed encouraging clinical activity in patients with metastatic melanoma in the phase I/II PIVOT-02 trial, according to a presentation during the 2020 Annual Meeting of the Society for ...
Expert Point of View: Karen M. Winkfield, MD, PhD
Moderator of the session, Karen M. Winkfield, MD, PhD, a radiation oncologist at Vanderbilt University Medical Center, and Executive Director of the Meharry-Vanderbilt Alliance in Nashville, underscored the importance of approaching patient survivorship holistically. “As radiation oncologists,...
Sexual Health: An Issue for Many Survivors of Cancer
Sexual dysfunction is prevalent among cancer survivors—and rarely addressed—according to data presented during the 2020 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 A survey of cancer survivors has found that nearly 9 out of 10 respondents reported some change after cancer...
Expert Point of View: Laura Dawson, MD
Laura Dawson, MD, Professor of Radiation Oncology at the University of Toronto and Princess Margaret Cancer Centre, viewed these initial study results as “a strong signal with high promise.” “Radiation therapy improves local control and delays local disease progression in patients with pancreatic...
